OPA Focusing on 340B Drug Pricing Transparency and Accuracy

by Admin | February 7, 2014 2:33 pm

February 7, 2014—The Health Resources and Services (HRSA) Office of Pharmacy Affairs (OPA) is developing ways to improve 340B pricing transparency and accuracy by drug manufacturers, OPA Director Cmdr. Krista Pedley said yesterday during the 340B Coalition winter conference in San Diego. Pedley addressed the gathering of more than 900 stakeholders remotely from HRSA headquarters in suburban Washington.

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1]. Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:

Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2014/02/opa-focusing-on-340b-drug-pricing-transparency-and-accuracy/